Other languages X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Real-time Estimate Cboe BZX Other stock markets 10:03:56 2024-04-29 EDT			5-day change	1st Jan Change
1.115 ^USD	-4.29%		-17.65%	+33.57%

01:07pm	X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	DJ
12:30pm	X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	06:30am
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	12-09
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	11-03
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	11-03
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	23-10-31
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	23-10-18
X4 Pharmaceuticals Submits NDA to FDA for Mavorixafor to Treat WHIM Syndrome	23-09-05
X4 Pharmaceuticals Announces Submission of New Drug Application to U.S. Fda for Mavorixafor in Whim Syndrome	23-09-05
X4 Pharmaceuticals Files $300 Million Mixed Shelf	23-08-14
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer	23-08-09
X4 Pharmaceuticals Set to Join Russell 3000; Shares Rise	23-06-13
X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome	23-05-16
X4 Pharmaceuticals to Raise $65 Million from Private Placement; Shares Rise	23-05-16
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
X4 Pharmaceuticals, Inc. Announces Late-Breaking Abstract of Whim Phase 3 Clinical Data Accepted for Oral Presentation At the 2023 Annual Meeting of the Clinical Immunology Society	23-04-12
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-21
X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Other languages

Filters